I'll research PSKY before writing the preview. Let me start by gathering documents, news, and price data.Let me read the most recent earnings materials and pull price data plus broader news context.I have strong fundamentals. Let me check the latest on the pivotal August 3 court hearing and the pro forma leverage picture.I have everything I need. Here's the earnings preview.
This is a quarter where the fundamentals are almost a sideshow: PSKY's story going into the print is dominated by its ~$97 billion cash-and-stock acquisition of Warner Bros. Discovery (WBD) — a deal that a federal court has temporarily frozen, that Wall Street handicaps at roughly a coin flip, and that would saddle the combined company with ~$80 billion of debt. The standalone business is actually executing reasonably well; the equity is trading like the market is bracing for the deal's balance-sheet consequences (or its collapse).
PSKY has been a persistent underperformer in 2026. Shares opened the year around $13.18, briefly spiked to $13.51 the day the WBD merger agreement was signed (Feb 27), and have bled steadily lower since — hitting a low of $7.81 on July 30 before closing at $8.24 on Aug 3. That's roughly ‑37% year-to-date, with essentially the entire drawdown coinciding with the market digesting the WBD financing and leverage plan.
The read-through: this weakness is not a referendum on operating results (Q1 actually beat). It reflects (a) dilution fears from a ~$47B equity raise priced at a $12.00–$16.02 collar, (b) pro-forma leverage anxiety, and (c) rising deal-completion risk. Note WBD trades around $26, well below the $31/share cash offer — the ~16-19% spread is the market telling you it does not fully believe this closes on the current terms/timeline.
Management gave explicit Q2 guidance on the Q1 call. Consensus is effectively anchored to it:
| Metric | Q2'26 Guidance | vs. Q2'25 (predecessor) |
|---|---|---|
| Total revenue | $6.75B – $6.95B | ‑1% to +1% (Q2'25 = $6.849B) |
| Adj. EBITDA | $0.9B – $1.0B | +4% to +16% (Q2'25 = $863M) |
| Adj. EBITDA margin | ~13.9% at midpoint | up from 12.6% |
| Stock-based comp | ~$75M | — |
Full-year 2026 targets to keep in the back pocket: $30B revenue (+4%), $3.8B adj. EBITDA (12.7% margin), and FCF conversion of ~5% before ~$800M of transformation costs.
Things that make Q2 a softer-looking quarter by design: - A tough theatrical comp — Q2'25 included Mission: Impossible — The Final Reckoning. - Ad revenue decelerates as they lap the NCAA Final Four/Championship. - Paramount+ net subs will again look "flattish" QoQ because of the strategic exit of ~2 million international hard-bundle subscribers (a deliberate quality-over-quantity move, not underlying weakness). Watch for management to re-frame this around underlying net adds and ARPU. - Management flagged that profitability skews to the first half of the year, so a QoQ step-down from Q1's very strong $1.16B adj. EBITDA is expected and shouldn't be misread.
Bottom line for the numbers: the bar is set. The debate will be about the quality of the DTC ramp (subscription + advertising growth ex-Showtime) and whether the $3B+ efficiency program keeps flowing through to margins, more than about a revenue beat/miss of a few points.
Recall the new three-segment structure (Studios / Direct-to-Consumer / TV Media) with recast comparatives. Q1'26 was the reference point:
This is what will drive the stock and dominate the Q&A. Key facts an investor must hold:
Structure & price - $31.00/share in cash for WBD (~$77.8B to shareholders; ~$97.3B total consideration including debt settlement and equity awards). - A "ticking fee" of ~$0.00278/share/day kicks in if the deal closes after Sept 30, 2026 (capped at $0.25 per 90 days) — a small but telling nod to timeline risk.
How it's financed (and why the stock is under pressure) - Equity: ~$46.7B PIPE from the Lawrence J. Ellison Revocable Trust plus $250M from RedBird, syndicated to a marquee sovereign/institutional group — the Saudi PIF, Abu Dhabi's L'Imad, Qatar's QIA, and LionTree. The syndication price collar is $12.00 floor / $16.02 cap. With the stock at ~$8, pricing sits at the floor, meaning ~3.9 billion new Class B shares — a roughly 4x increase in the share count from ~1.1B today. That is the dilution overhang in one number. - Debt: $5B term loans + up to $51.9B of "New Permanent Financing" + a $49B bridge backstop, plus exchange offers converting ~$12.7B of WBD notes into second-lien secured notes. - Pro-forma leverage: the combined balance sheet carries roughly $80B+ of debt and generated a pro-forma net loss (‑$1.0B in Q1'26, ‑$5.8B in FY25 on the illustrative combination). The assumed ~7% cost on permanent financing implies ~$4B+ of annual interest. This is the "extremely elevated leverage ratio" the market keeps citing.
Regulatory / legal — the live wire (and why timing matters this week) - ✅ EU granted conditional approval (Jul 22); South Korea cleared. - ⚠️ A group of U.S. states sued to block the deal; a federal judge temporarily halted it, with a hearing on the calendar for August 3 — literally the day before earnings — and the no-close deadline pushed to August 18. - ⚠️ Reports indicate Paramount agreed to pause the merger until as late as June 2027 pending the litigation, and that Wall Street prices ~50/50 odds of completion. Some WBD executives are reportedly hoping the suit derails it. - 🕊️ California Governor Newsom has voiced concern about his own state's suit and is nudging AG Bonta toward a settlement — a potential positive catalyst. There's also chatter that divesting CNN could ease antitrust opposition.
Management had been guiding to a Q3'26 close; given the injunction and the reported June-2027 backstop, the single most important thing on this call is any update to closing timeline, confidence, and contingency plans (including the ticking-fee accrual and whether the bridge might get drawn).
Bull case - Standalone execution is genuinely improving: DTC swung to positive EBITDA, Paramount+ ARPU +14%, TV Media margins expanding via cost control, and the $3B+ efficiency program is "ahead of schedule." - Guidance looks achievable/conservative; a clean beat + reaffirmed full year would reassure. - Any settlement path (Newsom's posture, potential CNN divestiture) that de-risks the WBD close could unlock a large re-rating given how much bad news is priced in. - WBD would add enormous IP/scale and a real streaming challenger to Netflix/Disney.
Bear case - ~50/50 deal odds + a court injunction = binary, hard-to-underwrite risk. - If it closes: ~$80B debt, a pro-forma net loss, ~7% financing cost, and ~4x share dilution — a heavily levered turnaround in a secularly declining industry. - If it breaks: overhang lifts but you own a legacy-media asset still fighting cord-cutting, minus a strategic rationale, with a controlling shareholder (Ellison family, ~77.5% of Class A) whose interests may not align with minority Class B holders. - Linear/TV Media secular decline and lumpy theatrical remain structural headwinds.
Because guidance is already framed for a soft-optics Q2 (theatrical comp, flattish subs), a modest revenue miss inside the $6.75–6.95B range likely matters far less than management's commentary on the WBD close in the wake of the Aug 3 hearing. Expect the after-hours move to be driven by: - Deal timeline/confidence language (biggest swing factor), - DTC margin trajectory and reaffirmation (or not) of the $30B / $3.8B EBITDA full-year targets, - Any hint of a litigation settlement or divestiture (CNN) that changes deal odds.
Given the depressed share price and heavy skepticism already embedded, the risk/reward is asymmetric around deal news rather than EPS — position and size accordingly.
Note: A pivotal court hearing on the states' challenge was scheduled for Aug 3, the day before this report. Confirm that outcome before the call, as it likely reframes management's entire deal narrative. All operating figures reference PSKY's Q1'26 results and its own Q2/FY26 guidance; the merger financials are the company's illustrative pro-forma disclosures and assume a close that has not occurred.